T2 Biosystems Announces LOI For Partnership On Lyme Disease
T2 Biosystems Announces LOI For Partnership On Lyme Disease
T2 Biosystems: Hold Rating Maintained Amid Growth Prospects and Profitability Concerns
Earnings Call Summary | T2 Biosystems(TTOO.US) Q1 2024 Earnings Conference
The following is a summary of the T2 Biosystems, Inc. (TTOO) Q1 2024 Earnings Call Transcript:Financial Performance:T2 Biosystems reported Q1 2024 sepsis product revenue of $2.1 million, a 25% increas
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
Advances plan to launch T2Lyme Panel for detection of early Lyme diseaseFiled Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Re
Stocks to Watch: Palantir, Hims & Hers Health, Beyond, T2 Biosystems
By Ben Glickman Palantir's U.S. commercial revenue growth decelerated sequentially in the first quarter, increasing 40% compared to a 70% increase in the fourth quarter. U.S. government contract reve
T2 Biosystems Shares Soar on Narrower 1Q Loss, Plus Debt-to-Equity and Distribution Pacts
By Paul Ziobro Shares of T2 Biosystems soared in late trading Monday after the diagnostics company disclosed a narrower first-quarter loss, as well as steps to improve its balance sheet and expand di
T2 Biosystems | 10-Q: Quarterly report
T2 Biosystems Shares Are Trading Higher After the Company Reported Mixed Q1 Financial Results and Announced the Execution of a Territory Exclusive Distribution Agreement in Qatar.
T2 Biosystems Shares Are Trading Higher After the Company Reported Mixed Q1 Financial Results and Announced the Execution of a Territory Exclusive Distribution Agreement in Qatar.
T2 Biosystems Reiterates Guidance
Reiterated 2024 Financial OutlookThe Company continues to expect full year 2024 total sepsis product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 mill
T2 Biosystems Q1 2024 GAAP EPS $(2.66) Misses $(2.27) Estimate, Sales $2.061M Beat $2.000M Estimate
T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(2.66) per share which missed the analyst consensus estimate of $(2.27) by 17.18 percent. This is a 97.98 percent increase over losses of $(13
T2 Biosystems Announced Execution Of Territory Exclusive Distribution Agreement In Qatar; To Sell T2Dx Instruments, T2Bacteria Panel, T2Candida Panel And T2Resistance Panel Through Newly Appointed Distributor
T2 Biosystems Announced Execution Of Territory Exclusive Distribution Agreement In Qatar; To Sell T2Dx Instruments, T2Bacteria Panel, T2Candida Panel And T2Resistance Panel Through Newly Appointed Dis
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M
04:35 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M
T2 Biosystems 1Q Loss/Shr $2.66 >TTOO
T2 Biosystems 1Q Loss/Shr $2.66 >TTOO
T2 Biosystems 1Q Loss $13.5M >TTOO
T2 Biosystems 1Q Loss $13.5M >TTOO
Press Release: T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period LEXINGTON,
Press Release: T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan Into Equity
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity Strengthens balance sheet by reducing total debt by approximately 80% over the past year Filed Pursua
Ttoo T2 Biosystems Files For Offering Of Up To 3.32M Shares Of Common Stock Along With Series B-1 and Series B-2 Common Warrants
Ttoo T2 Biosystems Files For Offering Of Up To 3.32M Shares Of Common Stock Along With Series B-1 and Series B-2 Common Warrants
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
Filed Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIR
T2 Biosystems Announces First Quarter 2024 Financial Results
Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year periodLEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (
T2 Biosystems Q1 Earnings Preview
No Data